Denali Therapeutics (DNLI) Projected to Release Earnings on Tuesday

Denali Therapeutics (NASDAQ:DNLI) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.3222) per share and revenue of $12.22 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the business earned ($0.72) earnings per share. On average, analysts expect Denali Therapeutics to post ($2.70) EPS for the current fiscal year and ($2.45) EPS for the next fiscal year.

Denali Therapeutics Price Performance

DNLI stock traded down $0.08 during trading on Tuesday, reaching $18.58. 45,792 shares of the company were exchanged, compared to its average volume of 1,717,666. Denali Therapeutics has a twelve month low of $13.75 and a twelve month high of $27.30. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -6.49 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. The company has a 50-day moving average of $21.09 and a two-hundred day moving average of $21.19.

Analyst Ratings Changes

Several research firms have recently issued reports on DNLI. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. UBS Group increased their price objective on Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 target price on the stock. Morgan Stanley lifted their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Wedbush reissued an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a research note on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.85.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This trade represents a 1.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.70% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.